H3 K27M-Altered Diffuse Midline Gliomas: A Review

Karol Wiśniewski1,2, Andrew Ghaly1, Kate Drummond1,3, Andreas Fahlström1,4

1 Department of Neurosurgery, Royal Melbourne Hospital, Melbourne, Australia  
2 Department of Neurosurgery and Neurooncology, Medical University of Łódź, Łódź, Poland  
3 Department of Surgery, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia  
4 Department of Medical Sciences, Section of Neurosurgery, Uppsala University, Uppsala, Sweden

Address for correspondence Kate Drummond, MD, FRACS, Department of Neurosurgery, Royal Melbourne Hospital, Melbourne, Victoria 3051, Australia (e-mail: kate.drummond@mh.org.au).

Introduction

H3 K27M-altered diffuse midline gliomas (DMG) are a rare primary central nervous system (CNS) glioma subtype. This tumor was previously known, in children, as diffuse intrinsic pontine glioma (DIPG). However, genetic analysis showed that 80% of DIPG harbored an H3 K27 mutation associated with poor prognosis. Analysis of a wider cohort of tumors for this mutation expanded the classification in the World Health Organization (WHO) 2016 Update of Classification of Tumours of the CNS. In 2021, the WHO created a specific group of pediatric-type diffuse high-grade gliomas. The group consists of four tumors (DMG, H3 K27-altered; diffuse hemispheric glioma, H3 G34-mutant; diffuse pediatric-type high-grade glioma, H3-wildtype and IDH [isocitrate dehydrogenase]-wildtype; infant-type hemispheric glioma) that differ molecularly and prognostically (Table 1). DMG H3 K27-altered may also occur in the adult population. Additionally, childhood H3 K27-altered gliomas are more common in the brainstem, but more common in the thalamus in adults. Sadly, limited treatment options exist for these tumors, with radiotherapy the only treatment shown to improve overall survival.

Abstract

Diffuse midline glioma H3 K27M-altered is a recently renamed high-grade glioma in the 2021 World Health Organization (WHO) Classification of Central Nervous System Tumors, previously being labelled diffuse midline glioma H3 K27M-mutant in the 2016 update and diffuse intrinsic pontine glioma prior to 2016. After identification of multiple alterations causing H3 K27 hypomethylation, the definition of this tumor subtype was changed. To further characterize this new entity in both the pediatric and adult population, we conducted a review of the current literature, investigating genetic, epidemiological, clinical, radiological, histopathological, treatment and prognostic characteristics, particularly highlighting the differences between adults and children. This tumor is more common in children, and has a poorer prognosis.

Keywords

- diffuse midline glioma
- H3.1 or H3.2 K27-mutant
- H3-wildtype with EZHIP overexpression
- EGFR-mutant
- H3.3 K27-mutant

Methodology

We conducted a PubMed search up to July 31, 2022 using the terms “diffuse midline glioma” and “H3 K27M” that returned 110 articles. We excluded articles without or with incomplete abstracts, books and documents, conference articles published online: 2023-07-26

© 2023. The Author(s).  
This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)  
Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
abstracts, letters, editorials, comments, published errata, case reports, and retracted articles. Only articles in English were considered. The search was supplemented by reviewing the article reference lists (► Fig. 1). Overall, 96 articles were included in the study (as one of 97 articles originally identified was retracted). There has been an increase in the number of articles related to this tumor type published per year over the previous decade (► Fig. 2). Although a systematic review was attempted, the data was not, ultimately, appropriate for metaanalysis and therefore a rigorous integrative qualitative/narrative review was undertaken.

### Definition and Classification

**H3 K27M-Mutant Diffuse Midline Glioma**

In 2016, the WHO created a new tumor subtype, DMG H3 K27M-mutant, a diagnostic entity based on its epigenetic signature. The WHO criteria for diagnosis of DMG H3 K27M-mutant are described in ► Table 2.

**H3 K27-Altered Diffuse Midline Glioma**

Subsequently, in 2021, the WHO amended this classification to DMG H3 K27-altered to encompass the varying mechanisms that can lead to the epigenetic alteration

---

**Table 1** Subtype definitions for pediatric-type high-grade glioma

<table>
<thead>
<tr>
<th>Subtype definition</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>H3 K27M-Altered Diffuse Midline Gliomas</strong></td>
<td>Wiśniewski et al. 105</td>
</tr>
</tbody>
</table>
characteristic of this tumor type\textsuperscript{21,50} and based on these molecular changes distinguished four subtypes of DMG H3 K27-altered (\textsuperscript{-Table 3})\textsuperscript{76}:

- DMG, H3.3 K27-mutant,
- DMG, H3.1 or H3.2 K27-mutant,
- DMG, H3-wildtype with EZHIP overexpression,
- DMG, EGFR-mutant.

### Genetic Characteristics and Cell of Origin

The molecular profile of DMG H3 K27-altered is still under investigation. The timing of H3 K27M mutation in children and the effect on embryonic, neonatal, and childhood brain development have not been characterized.\textsuperscript{42} In addition, the relationship between spinal cord DMG and supratentorial DMG regarding genetic alterations is also not clear, but spinal cord high-grade glioma in children and adults frequently harbors H3 K27M mutations.\textsuperscript{66}

In a 2018 study by Castel et al, investigating the epigenetic profile of H3 K27M-mutant tumors in a group of 215 children with pediatric high grade gliomas, it was found that subtypes of H3 K27M-mutant tumors were more accurately differentiated based on their methylation profile and gene expression, rather than their location, particularly when comparing supra- and infratentorial tumors. This may suggest these subtypes arise from a different precursor or epigenetic reorganization.\textsuperscript{75} Up to now, there is no conclusive evidence regarding the cell of origin for these tumors, but a few studies suggest an oligodendrocyte precursor cell, due to the strong immunophenotypic resemblance of the tumor cells to oligodendrocytes and the temporal and spatial relationship of tumor incidence to the expression of the precursor cells in neural development.\textsuperscript{95} This was later supported in a study by Filbin et al in 2018, who also found that, compared to IDH-mutant gliomas, H3 K27M-mutant gliomas are largely composed of cells resembling oligodendrocyte precursor cells.\textsuperscript{71} They also reported that H3 K27M-mutant gliomas had a large component of highly undifferentiated cells with high proliferative index, consistent with their aggressive behavior compared to IDH-mutant glioma.\textsuperscript{71}

DMG H3 K27M-mutants are characterized by a somatic gain of function mutation that leads to a lysine 27 to methionine (p.lys27Met: K27M) substitution in histone 3 (H3) variants.\textsuperscript{92} The K27 residue is essential for all variants of the H3 histone, as methylation of K27 has an inhibitory effect
on gene transcription. Thus, H3 affects gene expression with a wide influence on cellular differentiation, proliferation, and epigenetic regulation. The H3 K27M mutation, causing reduced H3 K27 trimethylation, affects stability of genetic transcription, inhibiting cellular differentiation while conversely promoting proliferation, with overexpression of genes that promote gliomagenesis.

This K27M substitution affects histone variants H3.1 and H3.3 and results from mutations to the HIST1H3B/C or H3F3A genes, with the H3F3A gene being most commonly affected. H3.1K27M tumors are also associated with mutations in the ACVR1 (Activin A receptor type 1), while H3.3K27M gliomas are associated with a gain of function mutation of PDGFRα (platelet-derived growth factor receptor alpha) and loss of function p53 mutations. Interestingly, up to one-third of DMG H3 K27M-mutant have ACVR1 mutations. Alteration of function of this receptor induces hyperactive bone morphogenic protein (BMP) signaling, which arrests oligodendrocyte differentiation and is potentially tumorigenic. In H3 K27M-mutant mouse models, mice with additional ACVR1 mutations survive only 70 days compared to those without, which have an average survival of 180 days.

H3 K27 hypomethylation is not necessarily due to K27M mutation. In 2020, Castel et al, described a subgroup of DMG with EZHIP (enhancer of zest homolog inhibitory protein) overexpression and H3 K27 trimethylation loss, in the absence of a H3 K27M-mutation, in a cohort of 10 patients with diffuse pontine glioma. This has subsequently been confirmed by other groups. EZHIP binds to PRC 2 (polycomb repressive methyltransferase complex 2) through the EZH2 subunit. PRC2 is the complex responsible for modifying the lysine residue on histone 3, resulting in methylation of the H3 protein to HK27me3. By binding to PRC2, EZHIP leads to a reduction in HK27me3. H3 K27me3 hypomethylation leads to driver mutations that contribute to oncogene activation through gene expression alteration. These genetic alterations include, as mentioned above, TP53 loss, associated with radiotherapy resistance, tumor immortality and self-renewal of neural stem cells, and gain of function of PDGFR, associated with tumor cell proliferation, invasion, and migration. Finally, a subset of DMG H3 K27M-mutant has been associated with amplification or pathogenic mutation of the EGFR (epidermal growth factor receptor) and overexpression of EGFR is associated with aggressive behavior and migration. Conversely, prognosis is improved in those DMG H3 K27M-mutant tumor subtypes with RAS-MAPK pathway alterations, such as FGFR1 (fibroblast growth factor receptor). Additional genetic alterations described in these tumors involve PPM1D (protein phosphatase, Mg2+/Mn2+- dependent 1D, MYC proto-oncogene transcription factor family), NF1 (neurofibromin 1), ATRX (α-thalassemia mental retardation X-linked protein), CDK (cyclin dependent kinase)/CDK6, and CCND (cyclin) 1-3.

The prognosis of DMG H3 K27M-altered varies between the pediatric and adult population and some genomic differences are noted between the two populations. The H3.3 K27M mutation rate in adults is significantly higher than in children.6,8,65,73,82 However, H3.1 mutant DMG occur more often in the young.15,38 Molecular profiling reveals higher frequencies of ATRX loss and H3.3 mutation in adult than in pediatric H3 K27M-mutant DMG and loss of ATRX expression has been associated with improved survival.49,63 TERT (telomerase reverse transcriptase) promoter mutations and MGMT (O6-methylguanine DNA methyltransferase) promoter methylation is not detected in children, but are present in a few adult patients. Loss of ATRX expression is observed mainly in adult patients. TERT promoter mutations and MGMT promoter methylation are present in up to 50% of IDH WT (wildtype)/H3-WT gliomas, in opposition to H3 K27M-mutant DMG, where TERT promoter mutations occur in 0 to 10% and MGMT is usually not methylated. Similar to children, adults with H3 K27M-mutant tumors harbor TP53 and FGFR1 mutations. To a large extent, however, the molecular profile of DMG H3 K27M-altered

---

**Table 3** 20121 WHO classification criteria for DMG H3 K27-altered

<table>
<thead>
<tr>
<th>DMG H3 K27-altered criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infiltrative glioma</strong> and<strong>Loss of H3 p.K28me3 (K27me3) (immunohistochemistry)</strong> and<strong>Located in the midline and one of below</strong> H3 p.K28M (K27M) or p.K28I (K27I) mutation (for H3 K27−-mutant subtypes) or Pathogenic mutation or amplification of <strong>EGFR</strong> (for the <strong>EGFR</strong>-mutant subtype) or Overexpression of <strong>EZHIP</strong> (for the H3-wildtype with <strong>EZHIP</strong> overexpression subtype) or Methylation profile of one of the subtypes of DMG</td>
</tr>
</tbody>
</table>

Results from the molecular analysis that enable discrimination of the H3.1 or H3.2 p.K28 (K27)-mutant subtype from the H3.3 p.K28 (K27)-mutant subtype are desirable.

Abbreviations: DMG, diffuse midline glioma; EGFR, epidermal growth factor receptor gene; EZHIP, enhancer of zest homolog inhibitory protein; WHO, World Health Organization.
tumors in adults is similar to that in children and the key to novel treatments of these tumors is likely to be the development of epigenetic modulators (Table 4).\textsuperscript{48,77,86} Tumor diagnosis and monitoring using “liquid biopsy” to detect DMG H3K27-altered mutations in cell-free DNA (cfDNA) in cerebrospinal fluid (CSF) or blood is a promising alternative to biopsy of highly eloquent regions such as the brainstem. Ventricular CSF is more reliable than lumbar CSF samples.\textsuperscript{12}

Epidemiology

Our epidemiological understanding of DMG H3 K27M-altered DMG is still incomplete as the entity was only described in 2021.\textsuperscript{7} This tumor is more common in children than in adults, but the mechanism for the pediatric predilection is unclear (Table 4). Some studies have suggested that children are three times more likely than adults to have mutations in their H3F3A or HIST1H8 gene.\textsuperscript{77}

Of midline pediatric primary brain tumors, 80% are H3 K27M-altered, and they comprise 75% of all pediatric brainstem tumors.\textsuperscript{3,19,49} However, DMG constitute only 10 to 15% of pediatric brain tumors overall and the prevalence of DMG is estimated at 0.54 cases per 1 million person-years.\textsuperscript{69,83} DMG comprise only 3 to 5% of adult primary brain tumors.\textsuperscript{25,55}

Anatomical Location

DMG H3 K27-altered are almost exclusively located in midline CNS structures. In adults, the most common location is the thalamus, but the brainstem, cerebellum, corpus callosum, hypothalamus, cerebral hemispheres, and spinal cord have also been reported.\textsuperscript{54} In children, brainstem tumors predominate (Table 4)\textsuperscript{81} chiefly in the pons (51.9%), then in the thalamus/basal ganglia (36.5%) and spine (9.6%).\textsuperscript{15} This is in contrast to non-H3 K27-altered tumors that are more widely distributed in children (31.3% thalamus/basal ganglia, 31.3% spinal cord, 12.5% pons, 12.5% midbrain/tectum, 12.5% other intracranial locations).\textsuperscript{15} No difference in location has been found for H3.1 and H3.3 molecular subgroups.\textsuperscript{15} For spinal cord DMG H3 K27-altered, H3 K27M-mutated tumors have a greater propensity for the thoracic spine, but there is no difference in location between mutated and wildtype tumors.\textsuperscript{68}

<table>
<thead>
<tr>
<th>Location</th>
<th>Children</th>
<th>Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevalence</td>
<td>0.54 cases per 1 million person-years</td>
<td>3–5% of adult primary brain tumors</td>
</tr>
<tr>
<td>Clinical presentation</td>
<td>Ataxia, cranial nerve palsies, developmental regression</td>
<td>Focal neurological deficits, hemiparesis, ataxia and cranial nerve palsies</td>
</tr>
<tr>
<td>Radiological features</td>
<td>Nonspecific</td>
<td>Nonspecific</td>
</tr>
<tr>
<td>Histopathology features</td>
<td>No significant differences</td>
<td>No significant differences</td>
</tr>
<tr>
<td>Mutation in H3F3A or HIST1H8 gene</td>
<td>More frequently</td>
<td>Less frequently</td>
</tr>
<tr>
<td>Prognosis</td>
<td>Radiotherapy</td>
<td>Radiotherapy</td>
</tr>
</tbody>
</table>

Table 4 Comparison of DMG H3 K27-altered in children and adults

Clinical Presentation

Clinical Features of Cranial DMG H3 K27-Altered

The clinical presentation of DMG H3 K27-altered correlates with location. Focal neurological deficits, hemiparesis, ataxia and cranial nerve palsies, account for more than 50% of presentations.\textsuperscript{48} In patients who present with cranial nerve palsies, cranial nerves VI and VII are most commonly affected, but cranial nerves III, IV, and X have also been reported.\textsuperscript{57} Symptoms of raised intracranial pressure are not common, although impaired level of consciousness is reported.\textsuperscript{48} Interestingly, hydrocephalus at first presentation occurs in less than 10% of patients with DMG H3 K27-altered. In children, ataxia and cranial nerve palsies are frequent modes of presentation.\textsuperscript{24} Symptomatic intratumoral hemorrhage is rare, occurring in up to 6% of patients, and generally only symptomatic in the pediatric population.\textsuperscript{16,48} In contrast to other brainstem gliomas, DMG H3 K27-altered typically present with an acute course of months and in both adults and children, with an average duration of symptoms of 2 to 3 months (Table 4).\textsuperscript{24,40}

Clinical Features of Spinal Cord DMG H3 K27-Altered

In spinal cord DMG H3 K27-altered, the clinical presentation is generally non-specific, and varies with the spinal level. Local pain generally precedes the development of neurological signs and symptoms, which most commonly comprise ataxia, sphincter dysfunction, and limb weakness.\textsuperscript{31}

Abbreviation: DMG, diffuse midline gliomas.
Radiological Characteristics

Radiological Features of Cranial DMG H3 K27-Altered

DMG H3 K27-altered in both adults and children have similar radiological features, but no pathognomonic or unique imaging characteristics have been described when compared to other cranial gliomas apart from location.\(^8\) On T1-weighted magnetic resonance imaging (MRI), these tumors are hypointense and enhanced with contrast with a diffuse or heterogeneous pattern. On T2-weighted MRI, they have heterogeneous signal intensity.\(^5\) Contrast enhancement may be patchy, nodular, cystic, homogenous or ring-like, and rarely absent.\(^4,5\) Extensive spread can occur craniocaudally to involve the cerebral hemispheres and spinal cord, and there may be leptomeningeal spread. Cortical invasion and leptomeningeal tumor spread are usually related to normal expression of ATRX.\(^2\) Other MRI findings include peritumoral edema, diffusion restriction, and hemorrhage, with peritumoral edema most common.\(^3\) However, no studies have identified imaging features able to differentiate DMG H3 K27M-altered and other high-grade gliomas.\(^8\)

On diffusion-weighted imaging (DWI), DMG usually do not, or only mildly, restrict and this is correlated with the presence of the H3K27M-mutation. Differences between H3 K27M-mutant and wildtype DMG have been noted. DWI and MRI perfusion-weighted imaging may be useful

Fig. 3 Magnetic resonance imaging (MRI) of pediatric brainstem diffuse midline glioma (DMG)-H3 K27M-altered. (A) T1-weighted MRI. The tumor is hypointense. (B) T1-weighted contrast-enhanced MRI. There is minimal and heterogeneous enhancement. (C) T2-weighted MRI. The tumor is heterogeneously hyperintense.

Fig. 4 MRI of adult thalamic DMG-H3 K27M-altered. (A) T2-weighted MRI. The tumor is heterogeneously hyperintense. (B) Fluid attenuated inversion recovery MRI. The tumor is hyperintense. (C) T1-weighted contrast-enhanced MRI. There is significant heterogeneous enhancement. (D) Apparent diffusion coefficient MRI. There is minimal diffusion restriction. (E) Cerebral blood volume MRI. There is patchy increase in perfusion. (F) MR spectroscopy. A glial tumor trace is identified.
in preoperative prediction of H3 K27M-mutation status. The normalized tumoral and peritumoral relative apparent diffusion coefficient (rADC) values have been reported to be lower and the relative cerebral blood volume (rCBV) and the normalized maximum rCBV (nrCBV) values higher in DMG H3 K27M-mutant. It has also been suggested that lower minimum rADC values in DMG H3 K27M-mutant indicate more malignant histology, likely representing a more complex tissue microstructure. Multiparametric MRI-based radiomics models may be useful to predict H3 K27M-mutant status in DMG using ADC histogram parameters. Additionally, myo-inositol/creatine plus phosphocreatine (Ins/tCr) ratios were lower than in the wildtype DMG in both children and adults. Moreover, when comparing DMG H3 K27M-mutant with H3 K27M-wildtype tumors, significant differences were found in T2 signal intensity, with H3.1 and H3.3 mutant tumors demonstrating higher signal intensity and wildtype tumors demonstrating homogeneous T2 signal, and T1 signal homogeneity, with H3 K27M-mutants demonstrating more heterogeneous T1 signal (Table 5). No significant imaging differences have been found between H3.1 and H3.3 K27M mutant tumors (Figs. 3 and 4).

**Radiological Features of Spinal Cord DMG H3 K27-Altered**

Studies evaluating the radiological features of spinal cord DMG have demonstrated a predilection for the cervical spine. They are isointense on T1-weighted images and hyperintense on T2-weighted. They have either absent or heterogeneous peripheral enhancement. No significant difference has been described for MRI features of H3 K27M-mutant and H3 K27M wildtype tumors; however, spinal DMG H3 K27M-mutant tumors are more likely to display leisional hemorrhage.

**Pathology**

There are no significant histopathological differences between adult and pediatric DMG H3 K27-altered tumors. Macroscopically, DMG H3 K27-altered share similar appearances to other gliomas in that they are infiltrative, enlarge, and distort invaded structures and have associated necrosis and hemorrhage. Microscopically, tumor cells are generally small and monomorphic, but polymorphism similar to other gliomas may be seen. Microvascular proliferation, necrosis, and frequent mitoses may be seen but are not associated with prognosis. Perineural or perivascular clustering does not occur. According to the WHO 2021 classification, those tumors are grade IV, irrespective of histopathological appearance.

Immunophenotyping and molecular confirmation of characteristic mutations is essential for diagnosis. Typically, DMG H3 K27-altered stain positive for OLIG2, MAP2, and S100. GFAP (glial fibrillary acidic protein) immunoreactivity varies. The EGFR-mutant subtype often shows positive staining for GFAP and less commonly OLIG2 and SOX10. Antibodies against H3 p.K28M (K27M), H3 p. K28me3 (K27me3), and EZHIP (COrf67) combined with additional molecular analysis are key to confirm the diagnosis ([Figs. 5 and 6]).

**Treatment**

There is no effective treatment for DMG H3 K27M-altered DMG, including for chemotherapy and targeted molecular agents. There is a paucity of literature on treatment of the specific DMG H3 K27M-altered tumor subtypes; therefore, treatment decisions rely on studies addressing DMG in general. Due to the predominantly eloquent location of these tumors, surgical management is often limited to biopsy to avoid postoperative morbidity. The current mainstay of treatment is radiotherapy, which has been shown to provide a symptomatic and survival benefit with limited disease control.

**Radiotherapy in H3 K27M-Altered DMG**

Fractionated external beam radiotherapy is the mainstay for DMG H3 K27M-altered, due to the known effects in other gliomas. The current treatment regimen is 54 Gy in 30 fractions. In a systematic review by Gallito et al, 49 studies investigating the role of conventionally fractionated, hyperfractionated, and hypofractionated radiotherapy in DIPG were evaluated. Patients who received radiotherapy had a median survival of 11 months as opposed to 6 months without radiotherapy. The median survival of patients who received hyperfractionated, hypofractionated and conventionally fractionated radiotherapy was 7.9, 10.2, and 12 months, respectively.

**Table 5** Comparison of radiological features of DMG H3 K27M-mutant and wildtype

<table>
<thead>
<tr>
<th></th>
<th>DMG H3 K27M-mutant</th>
<th>DMG wildtype</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MRI</strong></td>
<td>Hyperintense on T2, heterogeneous intensity on T1</td>
<td>Homogeneous intensity on T1 and T2</td>
</tr>
<tr>
<td><strong>DWI</strong></td>
<td>Low rADC values</td>
<td>High rADC values</td>
</tr>
<tr>
<td><strong>PWI</strong></td>
<td>High rCBV and rCBV values</td>
<td>Low rCBV and rCBV values</td>
</tr>
<tr>
<td><strong>MR spectroscopy</strong></td>
<td>Low Ins/tCr ratios</td>
<td>High Ins/tCr ratios</td>
</tr>
</tbody>
</table>

Abbreviations: Cr, creatine; DMG, diffuse midline gliomas; DWI, diffusion-weighted imaging; Ins, inositol; MRI, magnetic resonance imaging; PWI, perfusion weighted imaging; rADC, relative apparent diffusion coefficient; rCBV, relative cerebral blood volume.
Despite no demonstrated impact on prognosis, chemotherapy is commonly used for DMG. However, even in combination with radiotherapy, chemotherapy has shown no survival benefit. The most common agent is temozolomide due to its demonstrated effect in other gliomas. Other chemotherapy and targeted agents, including panobinostat, gefitinib, thiotepa, and busulfan, have been trialed, with no benefit. In the study by Izzuddeen et al, children with DIPG were randomized to conventional fractionated radiotherapy or hypofractionated radiotherapy with concurrent temozolomide. The median survival was 11 and 12 months, respectively, with no significant difference, but the patients who received radiotherapy and chemotherapy had a higher incidence of hematological toxicity.
chemotherapy with carboplatin/cisplatin, etoposide, cyclophosphamide, and vincristine with radiotherapy, with no improved event-free survival rate compared to combination chemotherapy in DIPG. Patients receiving temozolomide and radiotherapy had a 1-year overall survival of 40%, compared to 32% in those receiving combination chemotherapy and radiotherapy. Interestingly, H3 K27M mutations cause DNA hypomethylation, including the MGMT promoter. Therefore, expression of MGMT in DMG H3 K27M-altered tumors will lead to temozolomide resistance in these patients.

Identification of new therapeutic targets and corresponding targeted therapies against them is an area of intense research and a detailed overview is beyond the scope of this review. Abe et al suggested ALK2 receptor inhibitors may benefit patients with DMG as the type I BMP receptor ALK2 is encoded by ACVR1 gene that is frequently mutated in DMG HIST1H3B-mutant, but not H3.3 H3 K27M-mutant tumors. This receptor mutation causes constitutive activation of the BMP signaling pathway that can also be activated in ACVR1-wildtype DMG. Thus, the use of ALK2 inhibitors may be warranted. The same group has suggested PARP (poly (ADP-ribose) polymerase) inhibitors as PARP-mediated base excision repair of damaged DNA. DMG cells express PARP, thus inhibiting this pathway may be a potential therapeutic option of more efficacious drugs with improved tolerability in a more convenient dosage format. Thus, intense ongoing research is required to give new hope to DMG patients.

**Surgery in H3 K27M-Altered DMG**

Given the eloquent location of DMG H3 K27M-altered, surgical resection is almost always contraindicated as no survival benefit has been demonstrated and there is a high risk of neurological deterioration and death. No randomized study to date has investigated the role of surgery in DMG. The primary aim of surgery is to obtain a biopsy for diagnosis, prognosis, and research. The single-center, retrospective study by Wang et al that investigated outcome for those with DMG H3 K27M-mutant of the spinal cord found that surgical treatment, including biopsy, subtotal resection, or aggressive resection, showed no significant survival benefit. Interestingly, another single-center, retrospective study by Dorfer et al reported that surgical resection, as opposed to biopsy, was associated with a statistically significant improvement in overall survival, in a pediatric population of both H3 K27M-mutant (14 patients) and H3 K27M-wildtype (35 patients) thalamic gliomas. However, this was associated with high postoperative surgical morbidity including ataxia, visual field defects, and hemiparesis. A separate analysis of the DMG H3 K27-mutant tumors was not done and due to the small number of patients, the inclusion of better prognosis patients with pilocytic astrocytoma (almost 50% of the cohort) and the retrospective data, this study should be interpreted with caution.

In the multicenter, retrospective study by Karremann et al, extent of resection was not associated with improved survival in adults and children with DMG H3 K27M-mutant and H3-wildtype tumors. A trend to shorter survival in patients in the H3 K27M-mutant group who underwent more than 90% resection compared to those with <90% resection was reported, with 10% 2-year survival for those with less than 90% resection and 0% for those with more than 90% resection. These findings were replicated by Park et al, who also reported surgical resection was not associated with increased survival in adults with DMG (21.9 vs. 20.4 months), including for gross total compared to subtotal resection (13.2 vs. 21.9 months). Similarly, in the review of adult and pediatric patients with H3 K37M-mutant DMG by Vuong et al, surgical resection was not associated with improved overall survival.

**Immunotherapy and Future Perspectives**

The search for novel therapies has intensified recently, particularly in relation to immunotherapy. Phase 1 studies of chimeric antigen receptor (CAR) T-cells (CAR-T cells) in patients with pontine DMG H3 K27M-mutant have demonstrated both radiological improvements, with reduced T2/FLAIR signal extent on MRI, and clinical improvement. There was, however, also CAR-T cell-mediated inflammation with brainstem edema and obstructive hydrocephalus or transient worsening of clinical deficits. Other forms of immunotherapy, including immune-modulatory and dendritic cell vaccines, have shown initial promise.

In children, crenolanib, a selective inhibitor of PDGFR-mediated phosphorylation, has shown promising early phase results. It was well tolerated at doses slightly higher than the established maximum tolerated dose in adults, with a similar toxicity spectrum. Combination treatments of personalized cytotoxic agents or targeted inhibitors, chosen based on molecular analysis of biopsied tissue, are being examined in ongoing trials. Additionally, novel methods of drug delivery, including CED (convection-enhancing delivery), with small volume infusions via intraparenchymal catheters or MRI-guided focused ultrasound that enhances focally drug delivery of targeted chemotherapeutics to brain tumors are being investigated to bypass the blood–brain barrier. In a study by Gojo et al, mutations identified in patients with H3 K27M-mutant tumors, including those in E545K, G118D, and ACVR1, were targeted in a personalized medicine approach. However, the median survival of 16.5 months for the treatment group was not different to 17.5 months for the control group. Chi et al reported a promising response using a selective dopamine receptor D2/3 antagonist. Clearly further research into new approaches is needed.
Prognosis

DMG H3 K27M-altered carry a poor prognosis for both adults and children, with a median survival around 1 year and a poorer prognosis compared to most other gliomas. In adults, prognosis does not vary by anatomical site.10 In children with DMG H3 K27M-mutant, the median survival is 9 to 15 months, except in children with NF1 for whom all DMG have an extremely poor prognosis, independent of the presence or absence of H3 K27M mutation.52

Adults fare slightly better with a median survival of 8 to 27.6 months.8,49,65,72,77 The mechanisms of this survival advantage are unknown; however, as pediatric DMG H3 K27M-mutant tumors occur more commonly in the brainstem, and adult tumors in the thalamus, location may be important, with a greater morbidity in brainstem tumors.10,49,73 Additionally, the molecular genetics of thalamic DMG H3 K27M-mutant tumors differ compared to those in the brainstem, including in expression of the CDK6, TP53, K27M, and IDH1 genes.86 Additionally, TP53 mutation has been reported as a poor prognostic indicator, but FGFR1 mutation and ATRX loss confers prolonged survival.25 Thus, the molecular characteristics are likely more important than location to predict prognosis and should be examined in all patients.

For spinal cord DMG, the H3 K27M mutation predicts a worse outcome than other gliomas, although thoracic tumors have a significantly better prognosis than cervical.37

Conclusion

DMG H3 K27-altered are uniformly fatal primary CNS tumors for which the biology is only beginning to be determined. Differences in location and prognosis between adults and children are not fully understood. Current treatments are ineffective with research efforts aimed at novel drug delivery mechanisms, targeted agents, and immunotherapy. Further investigation is clearly required to improve outcomes.

Conflict of Interest
K.W. reported financial support provided by the Polish National Agency for Academic Exchange (the Bekker Programme). All other authors reported no conflict of interest.

Acknowledgment
K.W. gratefully acknowledges financial support provided by the Polish National Agency for Academic Exchange (the Bekker Programme).

References

11 Mount CW, Gonzalez Castro LN. Advances in chimeric antigen receptor (CAR) T-cell therapies for the treatment of primary brain tumors. Antibodies (Basel) 2022;11(02):31
18 Tinkle CL, Broniscer A, Jiang J, et al. Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG. Neurooncol Adv 2021;3(01):vdb179
H3K27M-Altered Diffuse Midline Gliomas

Włodarczyk et al.

38 Li Q, Dong F, Jiang B, Zhang M. Exploring MRI characteristics of brain diffuse midline gliomas with the H3 K27M mutation using radiomics. Front Oncol 2021;11:646267
56 Vitanza NA, Monje M. Diffuse intrinsic pontine glioma: from diagnosis to next-generation clinical trials. Curr Treat Options Neurol 2019;21(08):37
59 Himes BT, Zhang L, Daniels DJ. Treatment strategies in diffuse midline gliomas with the H3K27M mutation: the role of convection-enhanced delivery in overcoming anatomic challenges. Front Oncol 2019;9:331